In Vitro Technologies

Permits and Restrictions	View Permits View Restrictions
Organism	Homo sapiens, human
Tissue	lung; derived from metastatic site: pleural effusion
Product Format	frozen
Morphology	epithelial
Culture Properties	aggregates in suspension; the cells grow in very large aggregates, and the aggregates are the only viable cell population
Biosafety Level	1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease	carcinoma; small cell lung cancer
Age	40 years
Gender	male
Ethnicity	Caucasian

Karyotype	This is a near triploid human cell line. The modal chromosome number is 58, occurring at 44% with polyploidy at 3%. Marker chromosomes der(1)t(1;709p13;p11), t(13q;?HSR;15q) and der(190t(19;?)(q13.4;?) were common to most cells., There were two distinct subpopulations readily distinguished by karyotype. Besides uniform changes in the numbers of copies of some normal chromosomes, one population had der(3)t(3;20)(p11;p11?), t(3q19p), i(7q) and a minute chromosome of unknown origin., The other had t(1q17p), del(1)(q21), der(3)t(3;7)(p12;q11) plus two other markers. Each cell had two copies of a normal X chromosome. The Y chromosome was not detected in Q banded preparations.
Derivation	The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung. Derived from metastatic site, pleural effusion
Clinical Data	40 years Caucasian male The NCI-H82 cell line was derived by A.F. Gazdar and associates in 1978 from the pleural fluid of a patient with small cell cancer of the lung.
Receptor Expression	Insulin-like growth factor II (IGF II); atrial natriuretic peptide (ANP)
Oncogene	myc +; myb -; raf +; ras +; fms +; fes +
Tumorigenic	Yes
Effects	Yes, in nude mice
Comments	The morphology of the original tumor was not characteristic of SCLC. The line is a biochemical and morphological variant of SCLC that expresses neuron specific enolase and the brain isoenzyme of creatine kinase. It does not have detectable levels of L-DOPA decarboxylase or bombesin. The cells produce an abnormally sized p53 mRNA (3.7 kb). C-myc DNA sequences are amplified about 25 fold, and there is a 24 fold increase in c-myc RNA relative to normal cells. The cells are reported to express functional ANP receptors, but treatment with ANP does not alter their growth pattern. The cells stain positively for neurofilaments and vimentin. There is expression of v-fes, v-fms, Ha-ras, Ki-ras, N-ras and c-raf 1 mRNAs.

Complete Growth Medium	The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing	This line grows as aggregates of cells in suspension. Culture can be maintained by addition of medium or by replacement of medium. Alternatively, the cells may be collected by centrifugation and dispersed into fresh medium. Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:5 is recommended Medium Renewal: 2 to 3 times per week
Cryopreservation	Culture medium, 95%; DMSO, 5%
Culture Conditions	Temperature: 37°C

STR Profile	Amelogenin: X CSF1PO: 11 D13S317: 8 D16S539: 12 D5S818: 12 D7S820: 10,13 THO1: 9,9.3 TPOX: 11 vWA: 14
Isoenzymes	AK-1, 1 ES-D, 1 G6PD, B GLO-I, 1 Me-2, 1 PGM1, 1-2 PGM3, 1-2

Name of Depositor	AF Gazdar, JD Minna
Year of Origin	1978
References	Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024 The cells form transplantable tumors with non-typical SCLC histology.

Name of Depositor

AF Gazdar, JD Minna

Year of Origin

1978

References

Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141

Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067

Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257

Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258

Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370

Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389

Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760

Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024

The cells form transplantable tumors with non-typical SCLC histology.

Permits	These permits may be required for shipping this product to Australia: DAFF Import Permit formerly known as AQIS Import Permit must be obtained and a copy of the permit must be sent to ATCC in advance of shipment.
Basic Documentation	Product Sheet Certificate of Analysis SDS
Restrictions	The line is available with the following restrictions: This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. Any proposed commercial use of the these cells, or their products, must first be negotiated with the National Cancer Institute (NCI). For further information, please contact NCI’s Technology Transfer Center at NCI_TTC_Contact@mail.nih.gov or by phone at (240)-276-5514.
References	Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201 Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494 Schardt C, et al. Characterization of insulin-like growth factor II receptors in human small cell lung cancer cell lines. Exp. Cell Res. 204: 22-29, 1993. PubMed: 8380141 Gazdar AF, et al. Levels of creatine kinase and its BB isoenzyme in lung cancer specimens and cultures. Cancer Res. 41: 2773-2777, 1981. PubMed: 6265067 Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257 Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258 Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370 Ohsaki Y, et al. Human small cell lung cancer cell lines express functional atrial natriuretic peptide receptors. Cancer Res. 53: 3165-3171, 1993. PubMed: 8391389 Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 Rostomily RC, et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024 The cells form transplantable tumors with non-typical SCLC histology.

E: care@invitro.com.au
P: 1300 552 003

Request a quote or demo
Contact a Specialist

NCI-H82; Lung Carcinoma; Human (Homo sapiens) Item ID: ATCHTB175

Contact Us